Phase 3 N=219 Subject Preference for Scalp Psoriasis Treatment
Scalp Psoriasis
Primary: Percentage of Subjects Preffering Clobetasol Propionate Shampoo Better Than Comparator — 28.5; 31.6; 21.8 Percentage of participants — p=0.0003
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=124 Moderate to Severe Plaque Psoriasis With Scalp Involvement
Psoriasis
Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001
Phase 4 N=20 Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray
Psoriasis
Primary: Investigator Global Assessment (Scalp Only) — 1.59 score on a scale
Phase 3 N=371 Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis
Scalp Psoriasis
Primary: Proportion of Patients in Each Treatment Group Who Are Considered a Clinical Success — 49; 41 Participants — p=0.2961
Phase 2 N=3 Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
Scalp Psoriasis
Primary: Number of Participants With HPA Axis Suppression — 0; 2 Participants
Phase 3 N=303 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
Psoriasis
Primary: Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline — 13.7…
Phase 3 N=288 Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis
Scalp Psoriasis
Primary: Maintenance Phase: Time to First Relapse — 93.5; 56.8 days
Phase 3 N=373 Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis
Scalp Psoriasis
Primary: Clinical Success in Patients With Moderate and Severe Scalp Psoriasis — 41; 43 Participants — p=0.4557
Phase 3 N=231 Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
Scalp Psoriasis
Primary: The Proportion of Subjects With Investigator Global Assessment Mod 2011 (Scalp) Score of "Clear" and "Almost Clear" With at Least 2-point Reduction From Baseline at Week…
Phase 3 N=326 Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis
Scalp Seborrheic Dermatitis
Primary: Total Severity Score (TSS): Percent Change From Baseline at Week 4 — -71.4; -66.7; -66.7; -57.1 Percent change — p=<0.01
Phase 3 N=102 Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
Chronic Scalp Psoriasis
Primary: Psoriasis Scalp Severity Index 90 (PSSI 90) — 52.9; 2.0 Percent of Participants — p=<0.001
Phase 4 N=11 Evaluating the Efficacy and Tolerability of Application of Metaderm Product for the Treatment of Psoriasis
Psoriasis
Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…
Phase 4 N=81 Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp
Scalp Psoriasis
Primary: Number of Participants Who Were a Success or Failure Based on the Global Severity Score (GSS) of Scalp Psoriasis From Baseline to End of Treatment (Week 4 or Week 2 if…
Phase 4 N=89 A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
Psoriasis
Primary: Proportion of Patients Who Achieved a ≥ 75% Decrease in Psoriasis Scalp Severity Index (PSSI) Score at 12 Weeks — 0.111; 0.274 Proportion of patients — p=0.1054
Phase 2 N=71 CP-690-550 Ointment For Chronic Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — -53.97; -41.01; -24.26; -17.24 percent change
Phase 2 N=81 Topical CP-690,550 For Chronic Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — 2.38; -4.76; 2.48; -4.17 Percent Change
Phase 4 N=214 Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
Genital Psoriasis · Scalp Psoriasis
Primary: Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16 — 13.0; 69.1 percentage of…
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
Phase 2 N=77 Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult
Dermatitis, Seborrheic · Dry Skin; Eczema
Primary: Efficacy Determined Using the Investigator's Global Assessment (IGA) - Adult — 2.1; 1.1 units on a scale — p=<0.001
N/A N=291 A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
Plaque Psoriasis
Primary: Absolute Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9) Domain Total Score at Week 12 — 73.56; 72.07; 75.97 Score on a scale
Phase 4 N=20 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
Plaque Psoriasis
Primary: Subjective Subject Preference Survey for the First Treatment Session — 81.1; 77.6 units on a scale
Phase 4 N=154 Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
Psoriasis
Primary: Percentage of Participants With a Scalp-specific Physician Global Assessment Score of 0 or 1 (Ss-PGA 0/1) at Week 16 — 48.5; 13.7; 50.0; 12.8 Percentage of responders…
Phase 2 N=151 A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
Plaque Psoriasis
Primary: Clinical Response of Success — 6; 4; 6; 1 Participants — p=0.3571
N/A N=45 Alefacept in Patients With Severe Scalp Alopecia Areata
Alopecia Areata
Primary: The Proportion of Subjects Achieving at Least a 50% Reduction in Their Scalp Alopecia Areata Severity Scores (SALT Score) From Baseline Values — 8.7; 13.6 percentage of…
Phase 2 N=152 Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Psoriasis
Primary: Percent of Subjects With Treatment Success, Defined by at Least a 2 Grade Improvement From Baseline in the Investigator Global Assessment (IGA) Score Equating to Clear…
N/A N=506 Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
Moderate to Severe Plaque Psoriasis
Primary: Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) to Month 12 — -74.6 percent change
Phase 3 N=1,239 Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds
Psoriasis Vulgaris
Primary: Participants With "Controlled Disease" According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind…
Phase 3 N=120 Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Clinical Success — 18; 3 participants — p=0.0003
Phase 2 N=304 Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
Plaque Psoriasis
Primary: Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale — 107; 10 Participants — p=<0.0001
Phase 4 N=20 Topical Psoriasis Study for Patients Receiving Biologic Therapy
Psoriasis
Primary: Psoriasis Severity — 4.25 units on a scale